Vanda Pharmaceuticals Breaks Through With FDA Approval, Decision Date For Skin Drug

Vanda Pharmaceuticals (NASDAQ:VNDA) shares are up during Wednesday’s premarket session following the FDA’s approval of Bysanti, a new oral treatment for bipolar I disorder and schizophrenia, as well as the company’s rare skin disease drug is under FDA review.This approval marks a significant milestone for Vanda, as it positions the company to potentially capture a substantial market share in these therapeutic areas, which is reflected in the stock’s positive movement following the news.Seeks FDA Approval Fo ...